RAMESH AMIN: Open Payments
NPI 1427037514 · CONYERS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$323 in 15 payments from 9 companies in 2025. Trend: 2023 $99 · 2024 $256 · 2025 $323
Food & beverage: $323
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| Alkermes, Inc. | 2 | $38 |
| ABBVIE INC. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| Lundbeck LLC | 1 | $16 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: INGREZZA, ABILIFY MAINTENA, ARISTADA, REXULTI, VRAYLAR, HETLIOZ, CAPLYTA, INVEGA SUSTENNA.
Industry payments across GA — which companies pay providers there.
